Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 13/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 12/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22299266 | 0.88 | KMT2A (0.49) | KMT2AL3MBTL1MEN1NPC1ATM | |
| SCHEMBL12437175 | 0.84 | MEN1 (0.63) | KMT2AMEN1NPC1ATMNPSR1 | |
| SCHEMBL20932207 | 0.81 | L3MBTL1 (0.53) | KMT2AL3MBTL1MEN1 | |
| SCHEMBL13007693 | 0.73 | MEN1 (0.47) | KMT2AMEN1NPC1ATM | |
| SCHEMBL8477945 | 0.73 | KMT2A (0.50) | KMT2AL3MBTL1MEN1 | |
| SCHEMBL12569720 | 0.71 | KCNA5 (0.46) | KMT2AL3MBTL1NPSR1 | |
| SCHEMBL9164894 | 0.71 | GRM5 (0.47) | KMT2AL3MBTL1 | |
| SCHEMBL18889194 | 0.70 | CYP2D6 (0.47) | KMT2AL3MBTL1 | |
| SCHEMBL8251470 | 0.70 | CYP2D6 (0.47) | KMT2AL3MBTL1 | |
| SCHEMBL20711471 | 0.70 | MEN1 (0.50) | KMT2AMEN1NPC1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | MAPK1, MAPK11, MAPK14 | KMT2A 3774/4885L3MBTL1 3754/4885MEN1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.